Skip Navigation



Annals of Oncology Advance Access published online on November 6, 2007
Annals of Oncology, doi:10.1093/annonc/mdm509
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
19/3/465    most recent
mdm509v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Colleoni, M.
Right arrow Articles by Goldhirsch, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Colleoni, M.
Right arrow Articles by Goldhirsch, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy

M. Colleoni1,*, G. Viale2,3, D. Zahrieh4, L. Bottiglieri2, R. D. Gelber4, P. Veronesi3,5, A. Balduzzi1, R. Torrisi1, A. Luini3,5, M. Intra5, S. Dellapasqua1, A. Cardillo1, R. Ghisini1, G. Peruzzotti6 and A. Goldhirsch6

1 Unit of Research in Medical Senology, Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Milan
2 Division of Pathology, European Institute of Oncology
3 School of Medicine, University of Milan, Milan, Italy
4 International Breast Cancer Study Group, Statistical Center, Dana-Farber Cancer Institute, and Frontier Science and Technology Research Foundation, Boston, MA, USA
5 Division of Senology, European Institute of Oncology, Milan
6 Department of Medicine, European Institute of Oncology, Milan, Italy

* Correspondence to: Dr M. Colleoni, Unit of Research in Medical Senology, Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy. Tel: +39-02-57489439; Fax: +39-02-57489212; E-mail: marco.colleoni{at}ieo.it

Purpose: To identify the role of estrogen (ER), progesterone (PgR), epidermal growth factor 1 (HER1), and HER2 receptors in predicting response to preoperative chemotherapy.

Materials and methods: We reviewed the pretreatment biopsies of 485 patients with locally advanced breast cancer (cT2-T4, N0-2, M0) treated with preoperative chemotherapy. The incidence of pathological complete remission (pCR) and outcome were assessed with respect to clinical and pathological findings including ER/PgR status (absent versus expressed), HER1 (absent versus expressed) and HER2 (overexpressed versus none) expression.

Results: Patients with ER/PgR-absent tumors were 12.0 times [95% confidence interval (CI) 4.93–29.28] more likely to achieve a pCR (P < 0.0001). Predictors of disease-free survival (DFS) at the univariate analysis included HER1 [hazards ratio (HR) 1.6, 95% CI 1.04–2.32, P = 0.03] and HER2 (HR 1.6, 95% CI 1.08–2.38, P = 0.02) expression. A statistically significant difference in DFS was confirmed at the multivariate analysis for patients with ER/PgR-absent disease (HR 2.1, 95% CI 1.41–2.99, P = 0.0002).

Conclusions: The pCR rate is higher and outcome worse for patients with ER/PgR-absent tumors. HER1 and HER2 expression may have a prognostic role in locally advanced breast cancer and warrant further studies.

breast cancer, predictive factors, prognostic factors, primary chemotherapy

Received for publication July 13, 2007. Revision received October 1, 2007. Accepted for publication October 2, 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.